6 April 2015
The ‘shelf life’ of malaria-fighting drugs plays a significant role in how donors should subsidize the medicine in order to ensure better affordability for patients, a new report suggests. Forty percent of all malaria-caused deaths in sub-Saharan Africa occur in the Democratic Republic of Congo and Nigeria, according to the World Health Organization. The private sector “supply chain” manages 74% of the drug volume in Congo and 98% in Nigeria where malaria-stricken patients rely on “drug shops” and other for-profit retail outlets to get life-saving medicine.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/J1BYd81aK8c/150406082930.htm
